# Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

> **NCT04264819** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 295 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration

## Interventions

- **DRUG:** RTH258/Brolucizumab

## Key facts

- **NCT ID:** NCT04264819
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-14
- **Primary completion:** 2022-10-05
- **Final completion:** 2023-05-10
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04264819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04264819, "Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04264819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*